Merck & Co., Inc. $MRK Stock Sold by Community Trust & Investment Co.

Community Trust & Investment Co. decreased its holdings in Merck & Co., Inc. (NYSE:MRK) by 10.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 30,517 shares of the company’s stock after selling 3,748 shares during the period. Community Trust & Investment Co.’s holdings in Merck & Co., Inc. were worth $4,434,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently added to or reduced their stakes in MRK. Barlow Wealth Partners LLC lifted its position in shares of Merck & Co., Inc. by 1.3% in the 3rd quarter. Barlow Wealth Partners LLC now owns 7,590 shares of the company’s stock worth $1,077,000 after purchasing an additional 100 shares during the period. Saxony Capital Management LLC purchased a new position in shares of Merck & Co., Inc. in the 3rd quarter valued at $220,000. WealthPLAN Partners LLC lifted its stake in shares of Merck & Co., Inc. by 21.0% during the 3rd quarter. WealthPLAN Partners LLC now owns 7,267 shares of the company’s stock worth $1,056,000 after purchasing an additional 1,263 shares during the last quarter. Charles Schwab Trust Co grew its stake in Merck & Co., Inc. by 4.5% in the third quarter. Charles Schwab Trust Co now owns 8,622 shares of the company’s stock valued at $1,253,000 after purchasing an additional 372 shares during the last quarter. Finally, Turtle Creek Wealth Advisors LLC grew its position in shares of Merck & Co., Inc. by 7.2% in the 3rd quarter. Turtle Creek Wealth Advisors LLC now owns 31,052 shares of the company’s stock worth $4,512,000 after buying an additional 2,084 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Performance

Shares of Merck & Co., Inc. stock opened at $145.66 on Friday. Merck & Co., Inc. has a one year low of $82.01 and a one year high of $156.92. The company has a market cap of $359.37 billion, a price-to-earnings ratio of 116.53, a PEG ratio of 6.81 and a beta of 0.21. The business’s 50 day moving average price is $145.26 and its 200 day moving average price is $129.12. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. The firm had revenue of $16.61 billion for the quarter, compared to analysts’ expectations of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The firm’s quarterly revenue was up 5.1% on a year-over-year basis. During the same period in the prior year, the firm posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, research analysts predict that Merck & Co., Inc. will post 2.66 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th were issued a dividend of $0.85 per share. The ex-dividend date was Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.3%. Merck & Co., Inc.’s dividend payout ratio is 272.00%.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on MRK shares. Scotiabank upped their target price on Merck & Co., Inc. from $155.00 to $180.00 and gave the company a “sector outperform” rating in a research report on Tuesday, September 29th. Argus boosted their price target on Merck & Co., Inc. from $145.00 to $170.00 and gave the company a “buy” rating in a research note on Tuesday, August 25th. Daiwa Securities Group upgraded shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price target on the stock in a report on Wednesday, August 12th. UBS Group lifted their price objective on shares of Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Finally, Guggenheim raised their target price on shares of Merck & Co., Inc. from $146.00 to $170.00 and gave the stock a “buy” rating in a report on Tuesday, September 8th. Seventeen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $151.92.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck plans to present first-time pivotal Phase 3 data at ESMO 2026 for oncology programs including melanoma and endometrial cancer. The company will also hold an oncology investor event, potentially giving investors greater visibility into growth opportunities beyond Keytruda. What Could Merck Reveal At ESMO 2026 About Its Oncology Pipeline?
• Positive Sentiment: CEO Rob Davis said Merck and Moderna expect manufacturing of their personalized cancer vaccine to become faster over time. Improving production efficiency could support broader commercialization of the vaccine, although manufacturing remains complex. Merck CEO Tells CNBC He Expects Breakthrough Cancer Vaccine Will Become Faster to Make
• Neutral Sentiment: Analysts expect Keytruda sales growth, newer product launches and expanded indications to support third-quarter revenue. However, biosimilar competition is expected to become a more significant risk in 2028–2029, making pipeline execution increasingly important. Will Keytruda Continue to Aid Merck’s Top Line in Q3 Earnings?
• Neutral Sentiment: Merck’s dividend yield is about 2.3%, but comparisons with Amgen highlight differing levels of dividend coverage and cash-flow flexibility. The analysis may influence income-focused investors but does not introduce a new company-specific catalyst. AMGN vs. MRK: Which Pharma Giant’s Dividend Actually Has Room to Grow
• Negative Sentiment: Merck trades at a premium valuation of roughly 5.5 times sales, increasing the market’s expectations for sustained growth. Investors are also monitoring the changing emphasis in management’s strategy and continuing challenges for the Gardasil vaccine business in China. How Has Merck’s Story Changed?

Insider Activity

In related news, EVP Richard R. Deluca sold 11,699 shares of the company’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $131.63, for a total value of $1,539,939.37. Following the completion of the sale, the executive vice president directly owned 110,167 shares of the company’s stock, valued at $14,501,282.21. This represents a 9.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP David Williams sold 52,847 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the transaction, the executive vice president directly owned 31,716 shares in the company, valued at approximately $4,084,069.32. The trade was a 62.49% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is owned by corporate insiders.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.